Tuesday: FDA panel reviews Merck's Ragwiteck

Share this article:

Merck's prescription allergy medication Ragwitek is going before the FDA Allergenic Products Advisory Committee tomorrow, and the panel's discussion documents indicate the under-the-tongue medication is not associated with serious safety concerns, reports Reuters.

An FDA approval would provide an alternative to injections doctors typically give for pollen and ragweed allergies.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions